

# Erlotinib

**Catalog No: tcsc0620**



## Available Sizes

**Size:** 1g

**Size:** 2g

**Size:** 5g

**Size:** 10g



## Specifications

**CAS No:**

183321-74-6

**Formula:**

$C_{22}H_{23}N_3O_4$

**Pathway:**

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy

**Target:**

EGFR;EGFR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  50 mg/mL (127.08 mM)

**Alternative Names:**

NSC 718781;OSI-744;R1415

**Observed Molecular Weight:**

393.44


## Product Description

Erlotinib inhibits purified **EGFR** kinase with an **IC<sub>50</sub>** of 2 nM.

IC50 & Target: IC50: 2 nM (EGFR)<sup>[1]</sup>

**In Vitro:** Erlotinib (CP-358,774) is also a potent inhibitor of the recombinant intracellular (kinase) domain of the EGFR, with an IC<sub>50</sub> of 1 nM. The proliferation of DiFi cells is strongly inhibited by Erlotinib with an IC<sub>50</sub> of 100 nM for an 8-day proliferation assay<sup>[1]</sup>. The combination of B-DIM and Erlotinib (2 μM) results in a significant inhibition of colony formation in BxPC-3 cells when compared with either agent alone. The combination of B-DIM and Erlotinib (2 μM) results in a significant induction of apoptosis only in BxPC-3 cells when compare with the apoptotic effect of either agent alone<sup>[2]</sup>.

**In Vivo:** Under the experimental conditions, the combination of B-DIM and Erlotinib (50 mg/kg, i.p.) treatment shows significant decrease (P [2]. Erlotinib (20 mg/kg, p.o.) significantly attenuates Cisplatin (CP)-induced body weight (BW) loss when compared to the CP+vehicle (V) rats (P[3]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!